PROFLAVINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H11N3
Molecular Weight	209.2465
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

NC1=CC2=NC3=C(C=CC(N)=C3)C=C2C=C1

InChI

InChIKey=WDVSHHCDHLJJJR-UHFFFAOYSA-N

InChI=1S/C13H11N3/c14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10/h1-7H,14-15H2

HIDE SMILES / InChI

Molecular Formula	C13H11N3
Molecular Weight	209.2465
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Proflavine is an acriflavine derivative used as a topical disinfectant agains gram-positive bacteria. Proflavine is toxic and carcinogenic in mammals and so it is used only as a surface disinfectant or for treating superficial wounds. Proflavine acts by interchelating DNA (intercalation), thereby disrupting DNA synthesis and leading to high levels of mutation in the copied DNA strands. This prevents bacterial reproduction. Proflavine was investigated for photodynamic theraphy of herpes but was discontinued due to several presentations of post-treatment Bowen's disease and higher lesion recrudescence periods. Proflavine is also investigated as a topical contrast agent for imaging and diagnosis of esophageal, oral, colon, cervical, uterine cancer and polyps.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 278	Binding Agent 1,064
RNA 19	Binding Agent 1,064

Conditions

Condition	Modality	Highest Phase	Product
Gram-positive bacterial infections 8	Preventing	Approved 8,429	PROFLAVINE CREAM 0.1%
Genital herpes 13	Primary	Phase II 1,132	Unknown
Barrett’s esophagus 7	Diagnostic	Phase II 1,132	Unknown
Head and neck cancer 50	Diagnostic	Not Provided 504	Unknown
Cervical cancer 40	Diagnostic	Phase I 428	Unknown
Colon polyps 5	Diagnostic	Phase I 428	Unknown

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
001 Chemical	DY533450	https://www.001chemical.com/chem/1811-28-5
001 Chemical	DY580060	https://www.001chemical.com/chem/92-62-6
3B Scientific (Wuhan) Corp	3B2-4353	http://www.3bsc.com/index/pro_info.php?id=79293
Alfa Chemistry	ACM92626-1	https://mof.alfa-chemistry.com/product/3-6-acridinediamine-cas-92-62-6-295483.html
Alichem	449041438	http://www.alichem.com/en/products/92-62-6.html

Showing 1 to 5 of 26 entries

Previous1 2 3 4 5 6Next

PubMed

Show entries

Title	Date	PubMed
To dye or not to dye: a randomized, clinical trial of a triple dye/alcohol regime versus dry cord care.	2003 Jan	12509548
A biochemical logic gate using an enzyme and its inhibitor. Part II: The logic gate.	2003 Jun	12753934
A randomized study of 3 umbilical cord care regimens at home in thai neonates: comparison of time to umbilical cord separation, parental satisfaction and bacterial colonization.	2005 Jul	16241027
Time-resolved EPR spectra of the triplet excited states of diaminoacridine guests in polar potassium hydrogen phthalate single crystals.	2006 Jan 21	16482281

Showing 1 to 4 of 4 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

Proflavine cream 0.1% is indicated for topical use, to be applied to the affected part 2 - 3 times daily.

Route of Administration: Topical

In Vitro Use Guide

The minimal inhibition concentration (MIC) of proflavine with respect to various E.coli strains was determined by the twofold dilution method with LB agar containing the proflavine. Bacterial growth was recorded after 18 to 24 h of incubation at 37°C. Proflavine was effective in supressing bacterial growth at 6.5-12.5 ug/mL.